Jon Erik Gronbech
Overview
Explore the profile of Jon Erik Gronbech including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
174
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andersen G, Ianevski A, Resell M, Pojskic N, Rabben H, Geithus S, et al.
NPJ Syst Biol Appl
. 2024 Nov;
10(1):127.
PMID: 39496635
Biomarkers associated with the progression from gastric intestinal metaplasia (GIM) to gastric adenocarcinoma (GA), i.e., GA-related GIM, could provide valuable insights into identifying patients with increased risk for GA. The...
2.
Labori K, Bratlie S, Andersson B, Angelsen J, Biorserud C, Bjornsson B, et al.
Lancet Gastroenterol Hepatol
. 2024 Jan;
9(3):205-217.
PMID: 38237621
Background: In patients undergoing resection for pancreatic cancer, adjuvant modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) improves overall survival compared with alternative chemotherapy regimens. We aimed to compare the efficacy...
3.
Sando A, Gronbech J, Bringeland E
Acta Oncol
. 2023 Oct;
62(12):1846-1853.
PMID: 37903117
Background: Following neoadjuvant chemotherapy (NAC) for resectable gastric cancer, the prognostic adequacy of the UICC staging system needs to be investigated. In particular to explore whether the ypTNM curves for...
4.
Storli P, Dille-Amdam R, Skjaerseth G, Gran M, Myklebust T, Gronbech J, et al.
Acta Oncol
. 2023 Oct;
62(12):1822-1830.
PMID: 37862319
Background: Updated knowledge about the rates of recurrence and time to recurrence following curative treatment of colorectal cancer is essential to secure better patient information on prognosis, to serve as...
5.
Sando A, Fougner R, Royset E, Dai H, Gronbech J, Bringeland E
Cancers (Basel)
. 2023 May;
15(8).
PMID: 37190246
Background: The method of response evaluation following neoadjuvant chemotherapy (NAC) in resectable gastric cancer has been widely debated. An essential prerequisite is the ability to stratify patients into subsets of...
6.
Ness-Jensen E, Bringeland E, Mjones P, Lagergren J, Gronbech J, Waldum H, et al.
Scand J Gastroenterol
. 2022 Jan;
57(5):558-565.
PMID: 35068320
Hypergastrinemia increases the risk of developing proximal gastric adenocarcinoma. However, it is unclear if hypergastrinemia affects the survival in patients with gastric adenocarcinoma. This study aimed to examine the hypothesis...
7.
Yaqub S, Bjornbeth B, Angelsen J, Fristrup C, Gronbech J, Hemmingsson O, et al.
Trials
. 2021 Sep;
22(1):642.
PMID: 34544470
Background: Colorectal cancer is one the most common cancers in the western world with increasing incidence. Approximately 50% of the patients develop liver metastases. Resection of liver metastases is the...
8.
Sando A, Fougner R, Gronbech J, Bringeland E
World J Surg Oncol
. 2021 Jul;
19(1):212.
PMID: 34256790
Background: Response evaluation following neoadjuvant chemotherapy (NAC) in gastric cancer is debated. The aim of this study was to investigate the value of UICC-downstaging as mode of response evaluation following...
9.
Rabben H, Andersen G, Ianevski A, Olsen M, Kainov D, Gronbech J, et al.
Front Pharmacol
. 2021 Apr;
12:625991.
PMID: 33867984
The aim of the present study was repositioning of ivermectin in treatment of gastric cancer (GC) by computational prediction based on gene expression profiles of human and mouse model of...
10.
Rabben H, Andersen G, Olsen M, Overby A, Ianevski A, Kainov D, et al.
iScience
. 2021 Feb;
24(2):102091.
PMID: 33598644
Tumors comprise cancer cells and the associated stromal and immune/inflammatory cells, i.e., tumor microenvironment (TME). Here, we identify a metabolic signature of human and mouse model of gastric cancer and...